Dec 19 (Reuters) - TNF Pharmaceuticals Inc TNFA.O:
TNF PHARMACEUTICALS ANNOUNCES TRIAL TO EXPLORE EFFECTS OF LEAD CANDIDATE IN SARCOPENIA/FRAILTY INDUCED BY GLP-1 WEIGHT LOSS DRUGS
FULLY FUNDED STUDY TO EVALUATE WEGOVY AND OZEMPIC PATIENTS AT RISK FOR INCREASED INFLAMMATION ASSOCIATED WITH SARCOPENIC MUSCLE DETERIORATION
ENTERS COLLABORATIVE AGREEMENT WITH RENOVA HEALTH
Source text: ID:nBw9jKjzfa
Further company coverage: TNFA.O
((Reuters.Briefs@thomsonreuters.com;))